Company intelligence / Profile preview

ORPH Pharma IP Company

Dublin, Ireland

Ownership: Private
Development stage: Other

Overview

ORPH Pharma IP Company is a pharmaceutical entity focused on the development and commercialization of treatments for rare and orphan diseases. The company is best known for its involvement with cysteamine bitartrate formulations, specifically the delayed-release product Procysbi, used in the management of nephropathic cystinosis. ORPH Pharma operates primarily as an intellectual property holding and development vehicle, managing clinical assets and regulatory approvals for specialized metabolic disorders. Its business model centers on addressing high unmet medical needs within niche patient populations through targeted therapeutic interventions.

Therapeutic areas: Rare DiseasesNephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

Chiesi FarmaceuticiHorizon Therapeutics

Beyond the preview

Go deeper on ORPH Pharma IP Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORPH Pharma IP Company.

Explore the full profile